Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cerus Corporation develops and commercializes the INTERCEPT Blood System, a pathogen reduction technology designed to inactivate viruses, bacteria, parasites, and white blood cells in donated blood components such as platelets, plasma, and red blood cells. Serving blood centers, hospitals, and healthcare providers globally, Cerus aims to enhance blood safety by reducing transfusion-transmitted infections. Its business model relies on regulatory approvals, direct sales, and distributor partnerships across multiple international markets.
This description was generated via AI from an annual report. Updated about 1 year ago.